MLTX — MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
- Exchange: NASDAQ
- Employees: 100
- Website: https://www.moonlaketx.com
Latest SEC filings for MLTX
- 8-K — 2026-09-30
- SCHEDULE 13G/A — 2026-08-14
- S-8 — 2026-08-10
- S-3ASR — 2026-08-10
- S-3ASR — 2026-08-10
- 10-Q — 2026-08-10
- 8-K — 2026-08-10
- 8-K — 2026-07-15
- SCHEDULE 13D/A — 2026-06-29
- 8-K — 2026-06-25
Latest MLTX news
- — MoonLake’s sonelokimab faces regulatory, commercial tests, RBC says (seekingalpha_market)
- — MoonLake Immunotherapeutics submits sonelokimab BLA (seekingalpha_market)
Educational tool only — not investment advice.